JPRN-UMIN000001703已完成2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine in advanced biliary tract cancer (GS-COMBI). - Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine in advanced biliary tract cancer (GS-COMBI).
Japanese Endoscopist & IVRists group for Biliary Tract Cancer (JEIBIC)0 个研究点目标入组 62 人开始时间: 2009年2月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with an active concomitant infection 2) Patients with digestive ulcer or gastrointestinal bleeding 3) Patients with an active pulmonary fibrosis or interstitial pneumonia 4) Patients with an active concomitant malignancy 5) Pregnant, lactating female and patients of reproductive potential who did not use effective contraception 6) Patients with a previous history of a severe drug hypersensitivity 7) Patients receiving anti-cancer drugs 8) Patients with uncontrollable massive pleural effusion or massive ascites 9) Inappropriate patients for entry on this study in the judgement of the investigator
研究者
相似试验
已完成
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaJPRN-UMIN000021484Clinical study group of Osaka university, Hepato-Biliary- Pancreatic group100
招募中
2 期
PDAC-GS/GA-rP2JPRN-jRCTs051180122Kobayashi Syogo100
招募中
2 期
Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in patients with gemcitabine-refractory advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000007173Tokai University Hospital Kanagawa Cancer Center90
已完成
2 期
Randomized phase II study of Gemcitabine and S-1 combination therapy versus S-1 in patients with Gemcitabine-refractory unresectable advanced Pancreatic Cancerunresectable advanced Pancreatic CancerJPRN-UMIN000011806Osaka Pancreas Forum49
已完成
2 期
Phase II study of gemcitabine and S-1 combination therapy in advanced pancreatic cancer with malignant ascites.pancreatic cancer with ascitesJPRN-UMIN000003269ational Cancer Center Hospital East Hepatobiliary and Pancreatic Oncology Division36